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Abstract: KLF11 (Krüppel-like factor 11) belongs to the family of Sp1/Krüppel-like zinc finger
transcription factors that play important roles in a variety of cell types and tissues. KLF11 was initially
described as a transforming growth factor-beta (TGF-β) inducible immediate early gene (TIEG).
KLF11 promotes the effects of TGF-β on cell growth control by influencing the TGFβ–Smads signaling
pathway and regulating the transcription of genes that induce either apoptosis or cell cycle arrest.
In carcinogenesis, KLF11 can show diverse effects. Its function as a tumor suppressor gene can be
suppressed by phosphorylation of its binding domains via oncogenic pathways. However, KLF 11 can
itself also show tumor-promoting effects and seems to have a crucial role in the epithelial–mesenchymal
transition process. Here, we review the current knowledge about the function of KLF11 in cell
growth regulation. We focus on its transcriptional regulatory function and its influence on the TGF-β
signaling pathway. We further discuss its possible role in mediating crosstalk between various
signaling pathways in normal cell growth and in carcinogenesis.
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1. Introduction
The Krüppel protein regulates the body segmentation in the thorax and anterior abdomen of the
Drosophila embryo in Drosophila melanogaster [1]. Krüppel-like factors (KLFs) were first discovered in
1993 and named “Krüppel-like” as mammalian homologs of the Drosophila melanogaster gene Krüppel.
The first discovered KLF was named EKLF (also known as KLF1) [2]. Since then, diverse homologous
genes have emerged. All of them are now called the family of KLFs [3]. Currently, there are 17 known
KLFs in mammals. The functions of the family members are, in some cases, overlapping and, in others,
widely distinct [4]. KLFs can be divided into three subgroups based on structural and functional
features. Subgroups I and II of KLFs consist of KLF3, KLF5, KLF6, KLF7, KLF8, and KLF12 and of
KLF1, KLF2, KLF4, and KLF17, respectively. The remaining KLFs (KLF9, KLF10, KLF11, KLF13, KLF14,
KLF15, KLF16) belong to subgroup III [5].
Structurally, KLFs are composed of a conserved C-terminal region and widely divergent
N-terminal regions. The C-terminus consists of three tandem Cys2His2 zinc finger motifs, which act as
a DNA-binding domain. The zinc fingers bind GC-rich sequences (designated as Sp1 sites), including GC
boxes (GGGGCGGGG), GT/CACC boxes (GGTGTGGGG), and basic transcription elements (with
a preference for the 5′-CACCC-3′core motif), with varying affinities. These binding sequences are
widely distributed in promoters, enhancers, and locus control regions (LCRs) of housekeeping genes
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as well as of tissue-specific and viral genes [6,7] that are necessary for cell proliferation, differentiation,
apoptosis and morphogenesis [8–11]. The N-terminus contains the transcriptional regulatory domains
that vary significantly. It consists of acidic transactivation domains, Sin3 interacting domains (SID),
or C-terminal binding protein (CtBP)-binding repressor domains that can bind co-factors and contribute
to the distinct functions of KLFs [5]. The functions of Sin3 and CtBP might compete because the SID
and CtBP-binding domains overlap [5]. Only in several KLFs (KLF1, KLF4, KLF8, KLF11), the nuclear
localization signal (NLS)—which causes the nuclear localization of KLFs—is located immediately
adjacent to/within the zinc finger motifs. [12].
The transforming growth factor-beta (TGF-β) inducible immediate early gene (TIEG) encodes
a protein that has the ability to inhibit cell growth in cultured osteoblastic and epithelial cell
populations [13,14]. In 1998, a novel Sp1-like zinc finger encoding cDNA was identified, and the gene
product was named KLF11 [15]. KLF11 shows a high level of homology with TIEG and was named
TIEG2, accordingly. Since then, TIEG has been referred to as TIEG1 or KLF10 [15]. Both TIEG proteins
can be assigned to subgroup III of the KLFs. TIEG2 shares 91% homology within the C-terminal zinc
finger region with TIEG1 and 44% homology within the N-terminus. However, it does not share
any significant homology with any other previously identified protein [15]. TIEG1 and TIEG2 share
several proline-rich sequences within the N-terminal domain, a property commonly found in other
transcription factors as well [2,16–20]. Both TIEG proteins, like all members of subgroup III, share in the
N-terminus a conserved repression motif and an α-helical domain highly similar to the Sin3 interaction
domain (SID) of the transcriptional repressor Mad1 [1]. This SID-like domain mediates transcriptional
repression by interacting with the histone deacetylase corepressor complex mSin3A [21–23]. However,
the repressional function can be modified: The phosphorylation of different residues in a region
adjacent to the KLF11 SID-domain via the EGF–Ras–MEK1–ERK2 signaling pathway [24] and/or the
EGFR/AKT–KLF11 (Thr-56 phosphorylation) signaling pathway [25] disrupts the interaction of the
SID-like domain with mSin3A and results in a significant loss of the repressional function.
KLF11 plays a vital role in a variety of cell types and tissues. It potentiates TGF-β-mediated
anti-proliferative signaling pathways and thereby inhibits epithelial cell growth [15,26,27].
While TIEG2/KLF11 represents the human isoform [15], Tg3/KLF11 [28] is a murine isoform. Based on
the observations that KLF11 is significantly induced by TGF-β and, when artificially overexpressed,
mimics TGF-β–induced effects in various epithelial cell systems in vivo and in vitro, it has been
speculated that KLF11 might function as a TGF-β effector protein that participates in TGF-β signaling
pathways [15,29]. Within this review, we will focus on recent advances describing the different roles
and mechanisms of KLF11 between normal cell growth and cell growth disorders, which is particularly
important for future analyzes regarding the role of KLF11 in carcinogenesis and which may lead to
new insights and discoveries for cancer diagnosis or treatment.
2. Genomic Organization and Characteristic Structural Features of KLF11
KLF11 mRNA is ubiquitously expressed in human tissues, with the highest levels found in the
pancreas and in skeletal muscle [15]. It is a nuclear protein but is excluded from the nucleolus [15].
The transcriptional regulatory function of KLF11 is mediated by potent repressor activity located
within the N-terminal region of the protein [15]. Table 1 gives an overview of the genomic information
of KLF11 in Homo sapiens (humans). Chromosomal localization data refers to human genes and has
been obtained from the human genome database of the National Center for Biotechnology Information
(NCBI) (https://www.ncbi.nlm.nih.gov/gene).
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Table 1. Genomic information and aliases of human Krüppel-like factor 11 (KLF11).
Official Sambo KLF11
Official Full Name Krüppel-like factor 11
Gene Type protein coding
Organism Homo sapiens
Lineage
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
Euteleostomi; Mammalia; Eutheria; Euarchontoglires;
Primates; Haplorrhini;Catarrhini; Hominidae; Homo
Aliases FKLF; FKLF1; MODY7; TIEG2; Tieg3
Genomic Localization Chromosome 2 (2p25.1)
Transcriptional Activity (and Functional Domains) Activator/Repressor (SID, R2, R3)
Site of Expression Ubiquitous
Interacting Coactivator and /or Corepressor mSin3A
TIGE, TGF-β-inducible early gene; FKLF, fetal-beta like globin activating Krüppel-like factor; MODY7, maturity-onset
diabetes of the young type 7.
As a member of the KLFs family, the structure of KLF11 is characterized by the highly homologous
C-terminal DNA binding domain containing three Cys2His2 zinc finger motifs that bind the GC-rich
sequences (the Sp1-like sites) within promoters [1]. The “Sp1 site” dependent transcription can be
regulated: the activity, expression, and/or post-translation modification can be altered with cell growth.
A basic tetra peptide within the second and third zinc finger of the KLF11 DNA-binding domain
functions as an NLS, which is essential for it to be able to act as a site-specific transcription factor [15,30].
The N-terminal region of KLF11 consists of the three repression domains named R1, R2, and R3.
They can be tethered to the DNA through a heterologous DNA binding domain (DBD) to mediate
repression. The R1 domain, an alpha-helical repression motif (HRM), has been shown to be essential
for the interaction with the co-repressor mSin3A, and this interaction is followed by the inhibition of
the transcriptional activation of target genes [23]. Therefore, the R1 repression domain is often referred
to as the mSin3A interacting domain (SID) and seems to be the most important domain for facilitating
KLF11-mediated transcriptional repression [9,15,23].
3. KLF11, a Context-Dependent Transcriptional Repressor or Activator
KLFs are known to activate or repress gene expression in various organisms [31], subsequently
leading to context-dependent effects that might appear contradictory. TIEG1/KLF10 has been shown to
behave as a transcriptional repressor [32], and similarly, KLF11 represses promoter activity in vitro
and in vivo through the Sp1-like binding sites in the three repression domains [15]. However, the zinc
finger of KLF11 containing the DBD alone is able to activate the transcription [30].
KLF11 represses transcription through the recruitment of the mSin3A–histone deacetylase (HDAC)
complex via the SID [23]. Sequence analysis revealed that the SID is highly conserved within the
TIEG protein family, indicating that the recruitment of the HDAC complexes via binding mSin3A is
a general mechanism of transcriptional repression in these proteins [30]. Nevertheless, in HeLa cells,
KLF11-mediated transcriptional repression was not mSin3A-dependent, so the R2 and R3 domains
might also play an important role as transcriptional repressors [9,30]. However, the inhibition of
transcription by R2 and R3 is less well understood than the repression mediated by R1.
Although KLF11 was originally identified as a transcriptional repressor, recent studies have demonstrated
that it is also able to activate transcription in various cell types. Binding to the insulin promotor and activating
the transcription of the insulin gene, KLF11 plays a vital role in the function of the endocrine pancreas [33].
KLF11 could also interact with the co-activator p300 and activate the pancreatic-duodenal homeobox-1 gene
(Pdx-1), which is an important mediator of pancreatic beta-cell activity [34].
As KLF11 can behave as a transcriptional activator or as a repressor, it has been suggested that
the divergent function depends on the cell type and the promoter context [15,35]. The intramolecular
Int. J. Mol. Sci. 2020, 21, 2928 4 of 15
interactions of the N-terminal repression domains and the C-terminal activator domain, which could
be mediated by protein folding, have a counteracting activity in the context of the full-length state [30].
Thus, KLF11 might act as a context-dependent transcriptional repressor or activator by interacting
with coactivators or corepressors to orchestrate the transcriptional regulation of target genes.
4. KLF11 Contributes to the Regulation of Normal Cell Growth
TIEG proteins can act as growth-inhibiting and/or pro-apoptotic proteins in different cell
types [14,36–39]. Early research reported that KLF11 inhibits cell growth in pancreatic epithelial
cells [14,40] in an osteoblastic cell population [13] and in prostate cells through cell cycle regulation [41].
A proposed mechanism is the interaction with the TGF-β signaling pathway. TGF-β plays an important
role in the inhibition of cell growth, the regulation of extracellular matrix components, in cell
differentiation and migration, as well as in the induction of apoptosis. The intracellular signaling
pathway of TGF-β has been well elucidated [42–44]. In the TGF-β-signaling pathway, the Smad7
protein acts as a negative feedback loop that suppresses the TGF-β-induced growth inhibition. KLF11 is
now able to transcriptionally silence the Smad7 gene and to disrupt the negative feedback loop. Thereby,
KLF11 potentiates the TGF-β-signaling and the inhibitory effects of TGF-β on cell growth [45,46].
KLF11 can be induced by several members of the TGF-β superfamily, including all three TGF-β isoforms,
by activin, by BMPs, and by the glial-cell-derived neurotrophic factor [47]. Via transcriptional regulation
of further genes that induce apoptosis or cell cycle arrest, KLF11 can also inhibit proliferation [15,23,37].
The importance of KLF11 in cell growth regulation was firmly established by a study demonstrating
that its overexpression blocks the proliferation of Chinese hamster ovary (CHO) cells [15]. CHO cells
transfected with wild-type KLF11 showed decreased proliferation by 60% compared to cells that
were transfected with SID-deleted KLF11 or to normal control CHO cells [37]. Similarly, the PANC1
exocrine pancreatic epithelial cell line transfected with KLF11 showed a significant decrease in cell
proliferation and an increase in the number of apoptotic cells [37]. In vivo, transgenic expression of
KLF11 in the mouse exocrine pancreas resulted in decreased cell proliferation, increased apoptosis,
and reduced organ size [37]. KLF11-transgenic mice displayed downregulation of genes encoding
oxidative stress scavengers, such as superoxide dismutase 2 (SOD2) and catalase1, which might
contribute to an increased susceptibility to oxidative stress and increased cell death. In embryonic stem
cells, cell growth inhibition and transcriptional regulation were observed when KLF11 was transiently
or stably expressed [48]. In OLI-neu cells, KLF11 was described as a pro-apoptotic downstream
mediator of TGF-β [28,30].
Members of the Bcl-2 family are important regulators of apoptosis, deciding whether cells live or
die. The ratio between anti-apoptotic (e.g., Bcl-XL, Bcl-2) and pro-apoptotic (e.g., Bax, Bak) proteins
determines the susceptibility of cells to apoptosis [49]. The promoter region of Bcl-XL contains several
Sp1 sites serving as binding elements of KLFs [50]. KLF11 bridges the TGF-β-signaling to the repression
of anti-apoptotic Bcl-XL expression and thereby increases apoptosis. Overexpression of KLF11 in
OLI-neu cells resulted in apoptotic cell death accompanied by decreased levels of the anti-apoptotic
Bcl-XL [39]. On the other hand, KLF11 increased leiomyoma cell proliferation and abolished the
anti-proliferative effect of the progesterone antagonist RU486 via integrating with progesterone receptor
(PR) signaling [51].
However, one other in vivo study showed contrary effects with less importance of KLF11:
The KLF11 gene was inactivated in mice by gene knockout technology, and KLF11-/- mice were normal
in growth, bred according to the normal Mendelian genetics, and lived as long as KLF11+/+ mice.
Hematological analyzes also revealed no abnormalities in KLF11-/- mice [48].
In summary, KLF11 is highly induced by TGF-β and, when overexpressed, mimics the TGF-β
induced cell cycle arrest in epithelial cells. However, in vivo, the effects of KLF11 are less consistent
and show either inhibition of proliferation or normal cell growth (Table 2).
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Table 2. KLF11 in normal cells/tissues.
Biological Role Demonstrated Functional Effects Cell/Tissue Date Ref.
KLF11 preserves the structural
and functional integrity of the
blood-brain barrier
KLF11 activates the promotor of the tight
junction proteins occludin and ZO-1 Endothelial cells 2020 [52]
KLF11 induces apoptosis in
oligodendroglial cells
KLF11 induces apoptosis by decreasing the
levels of the anti-apoptotic protein Bcl-X(L)
and inhibiting the transcription of the protein
driven by the Bcl-X(L) promoter.
Murine
oligodendroglia cells 2007 [39]
KLF11 is a TGF-β-inducible
transcription factor with specific
domains.
The amino-terminus is essential for the
repressive transcriptional effects of KLF11.
When the mSin3A domain is lost,
the repressive effects are disrupted. The zinc
finger containing the DNA-binding domain
is essential for the nuclear localization of
KLF11 and is able to activate the
transcription of reporter genes.
Murine
oligodendroglial cells 2007 [30]
KLF11 is required for the
browning of human adipocytes
caused by PPARγ agonists like
rosiglitazone.
KLF11 is induced by PPARγ and increases
the mitochondrial oxidative capacity Human adipocytes 2015 [53]
KLF11 is involved in brown
adipocyte differentiation and is
highly expressed in brown
adipose tissue.
KLF11 induces the expression of the brown
adipocyte-specific gene UCP1 by interacting
with the UCP1 promotor via GC- and
GT-boxes.
Murine mesenchymal
stem cells 2010 [54]
KLF11 regulates the
estrogen-metabolizing enzyme
CYP3A4 in the endometrial
epithelium.
KLF11 expression was reduced in the
secretory phase endometrium and CYP3A4
was increased. Furthermore, KLF11
colocalized with the corepressor
SIN3A/histone deacetylase and repressed the
CYP3A4 promoter by deacetylation. This
repression was reversed by
a KLF11-mutation.
Uterine endometrium 2014 [55]
KLF11 inhibits gluconeogenesis
and improves glucose tolerance.
KLF11 inhibits the expression of the
gluconeogenic genes phosphoenolpyruvate
carboxykinase (cytosolic isoform, PEPCK-C)
and peroxisome proliferator-activated
receptor γ coactivator-1α (PGC-1α).
KLF11-overexpressing mice have less







KLF11 is involved in regulating
the insulin-production of
pancreatic beta cells.
KLF11 uses its zinc finger domain and
interacts with the coactivator p300 to activate
Pdx-1, which is an important mediator of
pancreatic beta-cell activity. Maturity onset
diabetes of the young (MODY7) variants of
KLF11 impair Pdx-1 activation ability.
Human pancreas islet
beta cells 2009 [34]
KLF11 inhibits the human
proinsulin gene expression.
KLF11 inhibits the proinsulin promotor by
binding a GC and a CACCC box
Human pancreatic beta
cells 2007 [57]
KLF11 regulates the insulin
production in pancreatic beta
cells
KLF11 binds to the insulin gene promoter
and regulate its activity. Two variants occur
in families with early-onset diabetes type 2;





inhibition induced by TGF-β
cells in pancreatic epithelial
cells.
Nuclear KLF11 and Smads3 bind to the core
region of the TGF-β inhibitory element of the
c-myc promotor and thereby inhibit
transcription and cell growth. KLF11
knockdown impairs the growth inhibition.
Human pancreatic
epithelial cells 2006 [40]
KLF11 mediates the TGF-β
induced growth inhibition by
potentiating the Smad-signaling
activity.
KLF11 terminates the inhibitory Smad7-loop
and therefore potentiates the Smad-signaling.
It recruits mSin3a via GC-rich sites to repress
the transcription from the Smad7 promoter.
Human pancreatic
epithelial cells 2004 [46]
5. The Relation of KLF11 to Cancers
Given the described role of KLF11 in growth regulation, it is not surprising that KLF11 has also
been implicated in the development of tumors. In carcinogenesis, the TGF-β signaling pathway
plays a dual role characterized by tumor suppression at early tumor stages and enhanced tumor
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progression at the late stages of the disease [43,59,60]. TGF-β mediates tumor suppression via
Smad-dependent signaling, which then regulates the transcription of cell-cycle-associated genes like
p15 and p21 [44,61]. But Smad7 also exerts a negative feedback loop by binding to the activated TβR-I,
blocking it and preventing phosphorylation [62,63]. Disturbances in the Smad-dependent signaling
have recently been shown in human cancers (including pancreatic cancer), and are associated with the
ability of tumor cells to escape from the TGF-β–induced growth inhibition [64,65]. TGF-β may also
signal through Smad-independent signaling cascades (e.g., Rho-like guanosine triphosphatases, p38,
mitogen-activated protein kinase [MAPK], phosphatidylinositol-3-kinase or c-Jun-N-terminal kinase)
and induce an epithelial-to-mesenchymal transition (EMT)—which is a key process in the formation of
cancer metastasis—of tumor cells, leading to enhanced tumor cell migration and invasion [66–70].
KLF11, as discussed above, is an early response transcription factor that potentiates the TGF-β
induced growth inhibition in normal epithelial cells by terminating the inhibitory Smad7 loop.
In pancreatic cancer cells with oncogenic Ras mutations, this function of KLF11 is inhibited by
the oncogenic Erk/MAPK: Erk/MAPK phosphorylates KLF11, which leads to the disruption of the
KLF11–mSin3a interaction [46]. This inhibits the binding of the KLF11–Smads complex to the
TIE element and leads to a reduced TGF-β-induced c-myc repression and to a reduction of the
anti-proliferative effects of TGF-β [40]. Another study showsd that KLF11 is inhibited in CHO cells
by the epidermal growth factor (EGF)–Ras–MEK1–ERK2 signaling pathway. Like in the Erk/MAPK
pathway, phosphorylation of four serine/threonine sites adjacent to the SID leads to the disruption
of the SID–mSin3A interaction [24]. In KRAS oncogenic mutant cancer cells, KLF11 inhibits BrdU
incorporation, increases apoptosis, and inhibits the KRAS-mediated foci and agar colony formation.
In vivo, KLF11 partly inhibits the growth of pancreatic tumor cells of KRAS mutant xenografts,
by inducing cell cycle arrest at the S phase via downregulation of cyclin A2 [11]. Therefore, KLF11 might
participate in the functional switch of TGF-β from a tumor suppressor to a tumor promoter. Figure 1
gives an overview of the different roles of the KLF11-mediated TGF-β–TGF-receptor–Smad signaling
pathway in normal cells and tumors.
In addition to the inhibition of KLF11 by SID phosphorylation via Erk/MAPK, Buttar et al. [25]
suggested an additional model of KLF11-mediated tumor suppression and its antagonism by
an oncogenic pathway. KLF11 binds to the GC-rich consensus sequences in the promoter region
of cPLA2α, the key rate-limiting enzyme of the oncogenic PGE2 cascade. Following binding,
KLF11 represses the cPLA2α promoter by recruiting the chromatin-remodeling complex Sin3a-HDAC
to the promotor. In this way, KLF11 behaves as a tumor suppressor gene by repression of the
cPLA2α–PGE2 pathway. This mechanism was shown in Barrett’s epithelial cells. EGFR-AKT signaling,
which is upregulated in a subset of patients during carcinogenesis in Barrett’s esophagus cancer, leads to
the phosphorylation of threonine at position 56 in the R1 domain (SID) of KLF11. This phosphorylation
inhibits the KLF11 binding, and the repression of the cPLA2α promoter and the tumor-suppressing
effects of KLF11 are inhibited. Probably EGFR can use two different intracellular pathways (ERK2
versus AKT) to inactivate KLF11 via phosphorylation. These phosphorylation events expand our
biochemical knowledge about KLF11 to the post-translational effects.
On the contrary, direct tumor-promoting effects of KLF11 have also been described.
In hepatocellular carcinoma, KLF11 had a significant influence on proliferation and apoptosis. It also
promoted local invasion and distant migration by suppressing the Smad7 transcription via binding to
the Smad7 promoter or by directly upregulating the Smad2/3 expression [71,72]. Ji Q et al. demonstrated
that the relative Twist1 promoter region activity increased gradually with increasing KLF11 levels in
the plasma [73]. Therefore, they speculated that KLF11 might regulate gastric cancer migration and
invasion by increasing the Twist1 expression, which is essential for EMT [73].
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KLF11. In normal cells, the KLF11-Sin3A-HDAC complex binds to the promoters of Smad7 and 
represses its expression, which acts as a negative feedback loop of the TGF-β–Smads signaling 
pathway. However, in some tumors, RAS was activated by tumor-promoting substances/growth 
factors. Ras phosphates KLF11 by the RAS–MEK–ERK pathway, which leads to the disruption of the 
KLF11–mSin3a interaction, resulting in the termination of the inhibitory KLF11-mediated Smad7 
loop. 
KLF11-methylation-dependent inactivation and downregulation occurs in several malignancies, 
including leukemia, myeloproliferative disorders, esophageal adenocarcinoma, pancreatic cancer, 
germ cell tumors, ovarian cancer, and head and neck cancer, supporting its candidacy as an actual 
tumor suppressor gene in humans [25,37,74–78]. KLF11 is involved in the progression of a wide 
Figure 1. KLF11-mediated modulation of the TGF-β signaling pathway in normal cells and tumors.
An activated TGF-β ligand binds to the type 2 domain of the TGF-β receptor, which then recruits
and phosphorylates a type 1 receptor. The type 1 receptor then recruits and phosphorylates
a receptor-regulated Smad (R-smad). The R-smad then binds to the common smad, Smad 4, and forms
a heterodimeric complex. The Smad complex translocates to the nucleus to induce the expression of
KLF11. In normal cells, the KLF11-Sin3A-HDAC complex binds to the promoters of Smad7 and represses
its expression, which acts as a negative feedback loop of the TGF-β–Smads signaling pathway. However,
in some tumors, RAS was activated by tumor-promoting substances/growth factors. Ras phosphates
KLF11 by the RAS–MEK–ERK pathway, which leads to the disruption of the KLF11–mSin3a interaction,
resulting in the termination of the inhibitory KLF11-mediated Smad7 loop.
KLF11-methylation-dependent inactivation and downregulation occurs in several malignancies,
including leukemia, myeloproliferative disorders, esophageal adenocarcinoma, pancreatic cancer,
germ cell tumors, ovarian cancer, and head and neck cancer, supporting its candidacy as an actual
tumor suppressor gene in humans [25,37,74–78]. KLF11 is involved in the progression of a wide variety
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of cancers, such as ovarian cancer and pancreatic cancer [40,78]. In breast cancer, the KLF11 promotor
is also hypermethylated, and the hypermethylation is associated with low expression of KLF11. KLF11
hypermethylation might be associated with higher rates of metastases [79]. Similar results were found
in uterine fibroids and in myelodysplastic syndrome [74,80], suggesting that DNA methylation to
regulate KLF11 expression might be a key event that directly contributes to tumorigenesis.
It was recently reported that the microRNA miR-30d increased the survival of BT474 and
MDA-MB-231 breast cancer cells. It was shown that it inhibited apoptosis and increased Bcl-2
expression, while it reduced the Bax protein levels. This influence of miR-30d on breast cancer cell
growth, metastasis, and EMT is dependent on a low level of KLF11 and on a high level of pSTAT3.
KLF11 is a direct target of miR-30d, and KLF11 and pSTAT3 expression are regulated by miR-30d [81].
MiR-30 also reduced the profibrogenic TGF-β signaling in hepatic stellate cells by suppressing
the KLF11 expression and thus enhancing the negative feedback loop of TGF-β signaling imposed by
Smad7 [82]. LincRNA-p21 reduced the availability of miR-30 [83]. Besides miR-30d, overexpression of
miR-10b in hepatocellular carcinoma (HCC) promoted HCC cell migration and invasion. MiR-10b
downregulated KLF4, which is the inhibitory transcriptional factor of KLF11. In this way, KLF11 was
upregulated, which promoted HCC EMT [72].
All these results suggest that KLF11 plays a crucial role during tumorigenesis and development.
(Table 3.).
Table 3. KLF11 in cancers.
Role in Cancer Demonstrated Functional Effects Cancers/CancerCell Type Date Ref.
KLF11 could be induced in non-small
cell lung cancer by radiohyperthermia
and might mediate the effects of
radiohyperthermia.
KLF11 induced apoptosis and inhibited cell
proliferation by elevating intracellular reactive






KLF11 mediates the tumor-promoting
effects of miRNA-30d in breast cancer.
MiRNA-30d increases breast cancer cell survival,
inhibits apoptosis, promotes migration and
invasion, and mediates the
epithelial–mesenchymal transition (EMT)
phenotype. MiRNA-30d exerts these effects by
targeting KLF11 and activating the STAT3 pathway.
Breast cancer 2018 [81]
KLF11-methylation might be
a biomarker for breast cancer
diagnosis and prognosis.
The median methylation levels of KLF11 were
≥30% higher than in normal samples. KLF11
methylation might also be associated with a higher
risk of metastasis.
Breast cancer 2012 [79]
KLF11 expression is reduced in
ovarian cancer.
KLF11 promoter DNA methylation results in
downregulated KLF11 expression accompanied by
reduced Smad2, Smad3, and Smad7 expression
Human ovarian
cancer 2015 [78]
KLF11 is upregulated in gastric cancer
an increases gastric cancer cell
migration and invasion.
KLF11 increases the Twist-1 expression in gastric




KLF11 inhibits prostaglandin E2
(PGE2) synthesis.
KLF11 represses the promotor of the
PGE2-synthesizing enzyme cytosolic
phospholipase A2∝ by binding and by recruiting
the Sin3-histone deacetylase chromatin remodeling





KLF11 mediates the-promoting effects
of miRNA-10b on EMT development
in hepatocellular carcinoma.
MiRNA-10b binds to the 3’UTR and downregulates
KLF4, which is an inhibitory transcriptional factor
of KLF11. Thereby, KLF11 is upregulated and
reduces the expression ofSmad7. This upregulates





KLF11 increases the monoamine
oxidase (MAO) B expression.
KLF11 increases MAO B at the promotor activity,
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Table 3. Cont.
Role in Cancer Demonstrated Functional Effects Cancers/CancerCell Type Date Ref.
KLF11 uses the epigenetic regulator
heterochromatin protein 1 (HP1) to
mediate tumor suppression.
KLF11 recruits HP1 and its histone
methyltransferase to promotors of cancer genes to
limit the KLF11-mediated gene activation.




KLF11 mediates growth inhibition;
the mechanism is disrupted in
pancreatic cancer.
In pancreatic cancer cells, the KLF11–Smad3
complex formation is disrupted and the
KLF11–Smad3 binding to the TGF-β-inhibitory
element of the c-myc-promotor is inhibited.




The KLF11-induced potentiating of
the TGF-β-signaling by the
termination of the inhibitory
Smad7-loop is inhibited in pancreatic
cancer.
In pancreatic cancer cells, an Erk/mitogen-activated
protein kinase phosphorylates KLF11, which leads
to a disruption of the KLF11–mSin3a interaction.
The KLF11–mSin3a repression of the Smad7
promotor is reduced, and therefore, Smad7




KLF11 is a tumor-suppressor gene
inactivated in myelodysplastic
syndromes (MDS).
KLF11 is hypermethylated in 15 % of MDS cases,
which is associated with a high International






In the last decade, the transcription factor KLF11 has come into focus in cancer research. However,
the characterization of the functions of KLF11 is still in its infancy. Recent data indicates that
KLF11 can affect cell growth and carcinogenesis through multiple mechanisms. KLF11 is not only
a basal promoter element involved in constitutive gene transcription but also plays multiple roles
in the modulation of transcription. It may respond to a particular signal in one cell type but not in
another, respond differently to the same signal, or respond to different signals differently in different
cells. It might act as a context-dependent transcription regulator and is linked to growth-related
biological processes.
Moreover, KLF11 might play an important role in the development of tumors. However, the role
of KLF11 in normal cell growth regulation and cancer is diverse, and other KLFs might induce relevant
transcription responses as well. Therefore, a full understanding of the role of KLF11 in growth
control and tumor progression will not only requires an analysis of the individual factor KLF11 but
also the identification of all KLFs expressed in the cells of interest and the characterization of the
transcriptional context.
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AKT protein kinase B (PKB)
AhR aryl hydrocarbon receptor
BC Breast Cancer
cDNA complementary Deoxyribonucleic Acid
CHO cells Chinese hamster ovary cells
COX1 cyclooxygenase-1
COX2 cyclooxygenase-2
cPLA2α cytosolic phospholipase A2α
CPTAC Clinical Proteomics Tumor Analysis Consortium
CtBP C-Terminal Binding Protein
DNA Deoxyribonucleic Acid
DNMT DNA methyl-transferase
DNMTis DNA methyltranferase inhibitors
EGFR Epidermal Growth Factor Receptor
EMT Epithelial–mesenchymal transition
EP3 prostaglandin E2 receptor 3
ER Estrogen receptor
ERK extracellular signal–regulated kinases
FKLF fetal-beta like globin activating krüppel-like factor
HDACis histone deacetylase inhibitors
KLF11 Krüppel like factors 11
LCRs locus control regions
LMU Ludwig Maximilians University
MAPK Mitogen-activated protein kinase
MEK Mitogen-activated protein kinase kinase
miRNA micro Ribonucleic Acid
MODY7 maturity-onset diabetes of the young type 7
NAC neo-adjuvant chemotherapy
PGE2 Prostaglandin E2
PI3K phosphatidylinositol 3 kinase
PPAR peroxisome proliferator-activated receptor
SIN3A SIN3 transcription regulator homologue A
SID mSin3 interaction domain
SMAD Mothers against decapentaplegic homolog
TFs transcriptional factors
TGF-β Transforming growth factor-beta
TIEG TGF-β inducible early gene
TLA Three letter acronym
LD linear dichroism
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